Lawrenceville, NJ , April 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering of 11,538,462 shares of common stock at a purchase price of $1.30 per share, resulting in net

Company reports further strengthening of R0 resection results in patients treated with GEN-1 LAWRENCEVILLE, N.J. , April 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that a

LAWRENCEVILLE, NJ , March 31, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 11,538,462 shares of its common stock at a purchase price of

Entered 2021 with a Focus on Cancer Immunotherapy and  Next-Generation Infectious Vaccines and a Strong Balance Sheet Conference Call Begins at 11:00 a.m. Eastern Time Today LAWRENCEVILLE, N.J. , March 19, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug

LAWRENCEVILLE, N.J. , March 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m.

LAWRENCEVILLE, N.J. , March 02, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that a poster on the Company’s Phase I/II OVATION 2 Study with GEN-1 in advanced

LAWRENCEVILLE, N.J. , Feb. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will be holding one-on-one meetings with investors during the Virtual 33

Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement To date 34 patients, or approximately one-third of the total, have been enrolled at 22 sites, including 20 patients in the treatment

Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years LAWRENCEVILLE, N.J. , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical stage development company focused on DNA based immunotherapy and next generation vaccines,

Celsion’s Commitment to Promoting Immune System Solutions to Fight Life-Threatening Diseases  Granted an Accelerated Development Pathway Designation Provides Potential for an Expedited Regulatory Review. LAWRENCEVILLE, N.J. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a